ARTICLE | Politics, Policy & Law
Jockeying for market exclusivity; RAC begins to resurface
July 21, 1997 7:00 AM UTC
Washington
WASHINGTON - Biotechnology and research-based pharmaceutical companies have reacted favorably to FDA's proposal to extend the marketing exclusivity period for newly approved products based on a single enantiomer of a previously approved racemate to five years from the current three-year period...